{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T01:48:12Z","timestamp":1648864092698},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,20]],"date-time":"2018-05-20T00:00:00Z","timestamp":1526774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13256-018-1580-8","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T16:23:35Z","timestamp":1525364615000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hydrochlorothiazide and risk of hearing disorder: a case series"],"prefix":"10.1186","volume":"12","author":[{"given":"Natnael","family":"Belai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selamawit","family":"Gebrehiwet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yodit","family":"Fitsum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulugeta","family":"Russom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,20]]},"reference":[{"key":"1580_CR1","volume-title":"Goodman and Gilman\u2019s pharmacological basis of therapeutics","author":"B Laurence","year":"2011","unstructured":"Laurence B, Bruce C, Bjorn K. Goodman and Gilman\u2019s pharmacological basis of therapeutics. 12th ed. New York: Mc Graw Hill; 2011.","edition":"12"},{"key":"1580_CR2","unstructured":"Mylan Pharmaceuticals. Product information for hydrochlorothiazide tablets, USP 12.5 mg, 25 mg and 50 mg. Revised in May 2011. Available at: \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/040735s004,040770s003lbl.pdf\n                    \n                  . Accessed 8 July 2017."},{"key":"1580_CR3","first-page":"601","volume":"15","author":"G Cianfrone","year":"2011","unstructured":"Cianfrone G, Pentangelo D, Cianfrone F, et al. Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide. Eur Rev Med Pharmacol Sci. 2011;15:601\u201336.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1580_CR4","unstructured":"Electronic Medicines Compendium (eMC). Summary of Product Characteristics of hydrochlorothiazide 25 mg and amiloride hydrochloride tablet. URL: \n                    https:\/\/www.medicines.org.uk\/EMC\/medicine\/17997\/SPC\/Moduret+25\/\n                    \n                  . Accessed 20 Aug 2017."},{"key":"1580_CR5","unstructured":"Medicines and Health Products Regulation. Summary of Product Characteristics of hydrochlorothiazide 25 mg tablet. Available at: \n                    http:\/\/www.mhra.gov.uk\/spc-pil\/?subsName=HYDROCHLOROTHIAZIDE&pageID=SecondLevel\n                    \n                  . Accessed 20 Aug 2017."},{"key":"1580_CR6","unstructured":"United States Food and Drug Administration. Hydrochlorothiazide prescribing information. Available at: \n                    www.drugs.com\/sfx\/hydrochlorothiazide-side-effects.html\n                    \n                  . Accessed on 23 Oct 2017."},{"key":"1580_CR7","unstructured":"QUALITEST PHARMACEUTICALS. Product information for hydrochlorothiazide tablets. URL: \n                    https:\/\/dailymed.nlm.nih.gov\/dailymed\/archives\/fdaDrugInfo.cfm?archiveid=69458\n                    \n                  . Revised December 2011. Accessed 31 Jan 2017."},{"key":"1580_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/00016480121545","volume":"121","author":"V Palomar Garcia","year":"2001","unstructured":"Palomar Garcia V, Abdulghani Martinez F, Bodet Agusti E, Andreu Mencia L, Palomar Asenjo V. Drug induced ototoxicity: current status. Acta Otolaryngol. 2001;121:569\u201372.","journal-title":"Acta Otolaryngol"},{"key":"1580_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2310\/7070.2007.0047","volume":"36","author":"P Mick","year":"2007","unstructured":"Mick P, Westerberg BD. Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin. J Otolaryngol. 2007;36:257\u201363.","journal-title":"J Otolaryngol"},{"key":"1580_CR10","unstructured":"Veda. \n                    http:\/\/vestibular.org\/ototoxicity\n                    \n                  . Accessed 8 July 2017."},{"key":"1580_CR11","doi-asserted-by":"publisher","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321. \n                    https:\/\/doi.org\/10.1007\/s002280050466","DOI":"10.1007\/s002280050466"},{"key":"1580_CR12","doi-asserted-by":"publisher","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369. \n                    https:\/\/doi.org\/10.1177\/0962280211403604","DOI":"10.1177\/0962280211403604"},{"issue":"6","key":"1580_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/00002018-200225060-00012","volume":"25","author":"SA Shakir","year":"2002","unstructured":"Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford\u2013Hill criteria. Drug Saf. 2002;25(6):467\u201371.","journal-title":"Drug Saf"},{"key":"1580_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimatingthe probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"1580_CR15","doi-asserted-by":"publisher","unstructured":"Brummett RE. Drug-induced Ototoxicity. Drugs. 1980;19(6):412\u201328. URL: \n                    https:\/\/doi.org\/10.2165\/00003495-198019060-00002","DOI":"10.2165\/00003495-198019060-00002"},{"issue":"2","key":"1580_CR16","first-page":"79","volume":"34","author":"A Sheppard","year":"2014","unstructured":"Sheppard A, Hayes SH, Chen GD, Ralli M, Salvi R. Review of salicylate-induced hearing loss, neurotoxicity, tinnitus and neuropathophysiology. Acta Otorhinolaryngol Ital. 2014;34(2):79\u201393.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"1580_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000106478","volume":"12","author":"E Van Eyken","year":"2007","unstructured":"Van Eyken E, Van Camp G, Van Laer L. The complexity of age-related hearing impairment: Contributing environmental and genetic factors. Audiol Neurootol. 2007;12:345\u201358.","journal-title":"Audiol Neurootol"},{"issue":"1","key":"1580_CR18","first-page":"63","volume":"13","author":"MFCG Mondelli","year":"2009","unstructured":"Mondelli MFCG, Lopes AC. Relation between arterial hypertension and hearing loss. Intl Arch Otorhinolaryngol. 2009;13(1):63\u20138.","journal-title":"Intl Arch Otorhinolaryngol"},{"key":"1580_CR19","first-page":"166","volume":"3","author":"SA Fausti","year":"1992","unstructured":"Fausti SA, Frey RH. Portable stimulus generator for obtaining high-frequency (8-14 Khz) auditory brainstem responses. J Am Acad Audiol. 1992;3:166\u201375.","journal-title":"J Am Acad Audiol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1580-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-018-1580-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1580-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T23:04:37Z","timestamp":1558307077000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-018-1580-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,20]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1580"],"URL":"https:\/\/doi.org\/10.1186\/s13256-018-1580-8","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,20]]},"assertion":[{"value":"15 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"135"}}